VIETER

行情报告详情

首页 · 行情 · 医药健康与生命科学

早期毒性检测市场主要参与者
医药健康与生命科学

早期毒性检测市场

Early Toxicity Testing Market

早期毒性检测市场:2026年市场规模约为16.2亿美元,2031年市场规模约为22.9亿美元;预测期复合年增长率为7.17%;当前最大市场为北美;增长最快的市场为亚太地区。

浏览1
更新时间2026-08-21
内容类型市场研究报告

市场研究正文

规模、增长、细分、驱动因素与关键问题

内容模板:完整版

当前质量分 100.00,审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。

核心结论

早期毒性检测市场:2026年市场规模约为16.2亿美元,2031年市场规模约为22.9亿美元;预测期复合年增长率为7.17%;当前最大市场为北美;增长最快的市场为亚太地区。

市场走势

结构化指标

指标年份数值性质
复合年增长率20317.17%机构预测
市场规模2026USD 1.62 billion机构预测
市场规模2031USD 2.29 billion机构预测

细分市场份额

drug development application · 202552.670%
pharmaceutical and biotechnology companies end_user · 202546.920%
North America geography · 202539.450%
cellular assays method · 202541.280%
services offering · 202534.760%
in vitro testing technique · 202558.430%
cell culture technology · 202536.540%
cytotoxicity testing toxicity_endpoint · 202523.810%

市场结构

维度细分项年份份额
applicationdrug development202552.670%
end_userpharmaceutical and biotechnology companies202546.920%
geographyNorth America202539.450%
methodcellular assays202541.280%
offeringservices202534.760%
techniquein vitro testing202558.430%
technologycell culture202536.540%
toxicity_endpointcytotoxicity testing202523.810%

关键结论

  • application 维度中,drug development 在 2025 年的公开份额为 52.67%。
  • end_user 维度中,pharmaceutical and biotechnology companies 在 2025 年的公开份额为 46.92%。
  • geography 维度中,North America 在 2025 年的公开份额为 39.45%。
  • method 维度中,cellular assays 在 2025 年的公开份额为 41.28%。
  • offering 维度中,services 在 2025 年的公开份额为 34.76%。
  • technique 维度中,in vitro testing 在 2025 年的公开份额为 58.43%。

主要参与者

  1. Thermo Fisher Scientific Inc.
  2. Charles River Laboratories International, Inc.
  3. Eurofins Scientific SE
  4. Merck KGaA
  5. Agilent Technologies, Inc.

增长驱动因素

因素影响 CAGR地区相关性影响周期
Rising Drug-Development Attrition and Safety De-Risking+2.100%Global, concentrated in North America, the EU, and JapanShort term (≤ 2 years)
Regulatory and Ethical Shift Toward New Approach Methods+1.800%Global (US, EU, APAC); regulatory influence particularly strong in North America and Western EuropeMedium term (2-4 years)
Human-Relevant Models for Translational Predictivity+1.300%North America and the EU; spill-over to APAC pharma hubsMedium term (2-4 years)
Outsourcing of Early Safety Workflows to Specialist CROs+1.100%North America, EU, and APAC core (China, India, South Korea)Short term (≤ 2 years)
AI-Ready Multimodal Toxicity Data for Design-Make-Test Cycles+0.800%North America and the EU, with early gains in APAC tech hubsShort to medium term (≤ 3 years)
Zebrafish and Developmental-Phenotype Screening for Rapid Hazard Triage+0.500%North America and Europe, national, with emerging activity in Singapore and South KoreaMedium term (2-4 years)

市场制约因素

因素影响 CAGR地区相关性影响周期
Limited External Validity for Complex Chronic and Multi-Organ Effects-0.600%GlobalLong term (≥ 4 years)
Regulatory Acceptance Gaps for Non-Animal Evidence Packages-0.500%Global; most acute in markets outside the United States and the EU with limited NAM guidanceMedium term (2-4 years)
Assay-Data Fragmentation and Proprietary Model Silos-0.300%GlobalShort to medium term (≤ 3 years)
Reproducibility Risk Across Advanced 3D and Microphysiological Systems-0.300%GlobalShort to medium term (≤ 3 years)

报告关注的关键问题

What is the size of the early toxicity testing market?

The early toxicity testing market was USD 1.62 billion in 2026 and is forecast to reach USD 2.29 billion by 2031, at a 7.17% CAGR.

Which testing technique has the largest share?

In vitro testing led with 58.43% in 2025, supported by its established role in cytotoxicity, genotoxicity, and ADMET testing.

Which application is growing fastest?

Cosmetics and personal care safety testing is forecast to grow at a 9.44% CAGR from 2026 to 2031, supported by demand for non-animal safety evidence.

Why are pharmaceutical companies outsourcing early safety work?

Specialized CROs provide access to diverse testing skills, regulatory knowledge, and infrastructure without requiring sponsors to build all capabilities internally.

How are NAMs affecting early toxicity testing?

NAMs are increasing demand for validated in vitro and computational methods as agencies in the United States and Europe advance non-animal safety frameworks.

市场概览

  • 增长最快市场:亚太地区
  • 最大市场:北美
  • 市场集中度:中等
Vieter 校准:机构预测不等于实际成交、订单、交付或出货。跨报告比较需要同时核对市场边界、基准年、币种及是否包含软件服务。本站不提供报告原文或全文译文。
查看来源:Mordor Intelligence